(Photo Courtesy: www.community.trapponline.com)
The upcoming event's theme mentions leveraging India to succeed globally and will focus on connecting the dots to build stakeholder consensus, and chart a distinct roadmap to propel the sector's growth.
BioAsia's CEO, Mr Shakthi Nagappan, exclusively shares with BioSpectrum about the inside happenings of BioAsia 2016. Though BioAsia's dates clashes with another biggest Biotech event, Bangalore India Bio 2016, he says BioAsia will confidently stand on the industry's support. Edited excerpts:
Q: How is BioAsia 2016 different from its previous editions?
A: Given the demonstrated success over the years in terms of investments, business partnering and quality of the deliberations, the Government of India through Department of Biotechnology (DBT) and Department of Pharmaceuticals is playing a very active role in planning and executing the 13th edition of BioAsia.
In addition to the core biotech and pharma focus, the next edition will also focus on healthcare leaders, technology companies, and entrepreneurial community aimed at connecting the cross sectoral stakeholders to enable cross-pollination of ideas.